Search Results

Displaying Results 1-2 of 2 "'WVE'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight

Jun 25, 2026, 10:31 ET Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight

Huntington's disease therapies in clinical trials include SKY-0515, Votoplam (PTC518), Pridopidine, Bevantolol (SOM3355), AMT-130, RG6042 (tominersen), WVE-003, ALN-HTT02, VO659, ANX-005, and others.Discover who will dominate the Huntington's disease therapy treatment by 2036 @

More news about: DelveInsight Business Research, LLP

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1

May 19, 2026, 09:49 ET Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1

delivering candidates that optimally address disease biology. Wave's pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington's disease, as

More news about: Alpha-1 Foundation

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.